Drug treatment of arthritis

References

• Upton RA, Williams RL, Kelly J, et al. Naproxen pharmacokinetics in the elderly. Br J Clin Pharmacol 1984: 18(2): 207–14
   PubMed Web of Science ®Google Scholar
• Brater DC, Lasseter KC. Profile of etodolac: pharmacokinetic evaluation in special populations. Clin Rheumatol 1989: 8(Suppl 1): 25–35
   PubMed Web of Science ®Google Scholar
• Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs: differences and similarities. N Engl J Med 1991;324(24): 1716–25 [erratum, N Engl J Med 1991: 325(10): 747]
   PubMed Web of Science ®Google Scholar
• Wu KK, Sanduja R, Tsai AL, et al. Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci USA 1991: 88(6): 2384–7
   PubMed Web of Science ®Google Scholar
• Abramson SB, Weissmann G. The mechanisms of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1989: 32(1): 1–9
   PubMed Web of Science ®Google Scholar
• Rossi AC, Hsu JP, Faich GA. Ulcerogenicity of piroxicam: an analysis of spontaneously reported data. BMJ 1987: 294(6565): 147–50
   PubMedGoogle Scholar
• Arnold JD, Salom IL, Berger AE, et al. Comparison of gastrointestinal microbleeding associated with use of etodolac, ibuprofen, indomethacin, and naproxen in normal subjects. Curr Ther Res 1985: 37(4): 730–8
   Web of Science ®Google Scholar
• Jallad NS, Sanda M, Salom IL, et al. Gastrointestinal blood loss in arthritic patients receiving chronic dosing with etodolac and piroxicam. Am J Med Sci 1986: 292(5): 272–6
   PubMed Web of Science ®Google Scholar
• Dvornik D, Lee DK. Selective sparing of cytoprotective prostaglandins: possible mechanisms for the gastric safety of etodolac. J Musculoskel Med 1991: 8(4 Suppl): S47–53
   Google Scholar
• Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991: 115(10): 787–96
   PubMed Web of Science ®Google Scholar
• Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med 1991: 115(3): 195–200
   PubMed Web of Science ®Google Scholar
• Ramos-Remus C, Sibley J, Russell AS. Steroids in rheumatoid arthritis: the honeymoon revisited. (Editorial) J Rheumatol 1992: 19(5): 667–70
   PubMed Web of Science ®Google Scholar
• Paulus HE. Antimalarial agents compared with or in combination with other disease-modifying antirheumatic drugs. Am J Med 1988: 85(4A): 45–52
   PubMed Web of Science ®Google Scholar
• Kremer JM. Methotrexate in rheumatoid arthritis. In: Furst DE, Weinblatt ME, eds. Immunomodulators in the rheumatic diseases. New York: M Dekker, 1990: 1–22
   Google Scholar
• Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum 1992: 35(2): 138–45
   PubMed Web of Science ®Google Scholar
• Williams HJ, Ward JR, Dahl SL, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988: 31(6): 702–13
   PubMed Web of Science ®Google Scholar
• Epstein WV, Henke CJ, Yelin EH, et al. Effect of parenterally administered gold therapy on the course of adult rheumatoid arthritis. Ann Intern Med 1991; 114(6): 437–44 [comments, Ann Intern Med 1991,114(11): 993–4, 1991;115(2): 155–6, 1991: 115(10): 825–7
   PubMed Web of Science ®Google Scholar
• Williams HJ, Dahl SL, Ward JR, et al. One-year experience in patients treated with auranofin following completion of a parallel, controlled trial comparing auranofin, gold sodium thiomalate, and placebo. Arthritis Rheum 1988: 31(1): 9–14
   PubMedGoogle Scholar
• Singh G, Fries JF, Spitz P, et al. Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective. Arthritis Rheum 1989: 32(7): 837–43
   PubMed Web of Science ®Google Scholar
• Pincus T. The paradox of effective therapies but poor long-term outcomes in rheumatoid arthritis. Semin Arthritis Rheum 1992: 21(6 Suppl 3): 2–15
   PubMed Web of Science ®Google Scholar
• Chalmers IM, Sitar DS, Hunter T. A one-year, open, prospective study of sulfasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status. J Rheumatol 1990: 17(6): 764–70
   PubMed Web of Science ®Google Scholar
• van Rijthoven AW, Dijkmans BA, Goeithe HS, et al. Long-term Cyclosporine therapy in rheumatoid arthritis. J Rheumatol 1991: 18(1): 19–23
   PubMed Web of Science ®Google Scholar
• Soden M, Hassan J, Scott DL, et al. Lymphoid irradiation in intractable rheumatoid arthritis: long-term followup of patients treated with 750 rads or 2,000 rads. Arthritis Rheum 1989: 32(5): 523–30
   PubMed Web of Science ®Google Scholar
• Riskin WG, Gillings DB, Scarlett JA. Amiprilose hydrochloride for rheumatoid arthritis. Ann Intern Med 1989: 111(6): 455–65
   PubMed Web of Science ®Google Scholar
• Kremer JM, Lawrence DA, Jubiz W, et al. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis: clinical and immunologic effects. Arthritis Rheum 1990: 33(6): 810–20
   PubMed Web of Science ®Google Scholar
• Horneff G, Burmester GR, Emmrich F, et al. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991: 34(2): 129–40
   PubMed Web of Science ®Google Scholar
• Sewell KL, Trentham DE. Rapid improvement in refractory rheumatoid arthritis by an interleukin-2 receptor targeted immunotherapy. (Abstr) Clin Res 1991: 39(2): 314A
   Google Scholar
• Willkens RF, Urowitz MB, Stablein DM, et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992: 35(8): 849–56
   PubMed Web of Science ®Google Scholar